Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To test the hypothesis that the modified N7 induction regimen will improve the metastatic response rates or event free survival (EFS) as compared to Rapid COJEC (R3 randomisation). - To test the hypothesis that the addition of subcutaneous aldesleukin (IL-2, (Proleukin®)) to immunotherapy with chimeric 14.18 anti-GD2 monoclonal antibody produced in Chinese hamster ovary (CHO) cells (ch14.18/CHO) given as continuous infusion in addition to differentiation therapy with isotretinoin (13-cis-RA) following myeloablative therapy (MAT) and autologous SCR, will improve EFS in patients with high-risk neuroblastoma (stage 4 disease or stages 2 and 3 with MYCN amplification, all over the age of one, or infants with MYCN amplification) (R4 randomisation).
Critère d'inclusion
- High Risk Neuroblastoma